Page last updated: 2024-09-05

erlotinib hydrochloride and pd 176252

erlotinib hydrochloride has been researched along with pd 176252 in 1 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (pd 176252)	Trials (pd 176252)	Recent Studies (post-2010) (pd 176252)
4,353	786	3,033	22	0	14

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bhola, NE; Grandis, JR; Gubish, CT; Lui, VW; Mills, GB; Shin, D; Siegfried, JM; Siwak, DR; Thomas, SM; Zhang, Q	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and pd 176252

Article	Year
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular cancer therapeutics, 2007, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Invasiveness; Quinazolines; Receptors, Bombesin; Signal Transduction; Tumor Stem Cell Assay	2007

Article

Year

Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

Molecular cancer therapeutics, 2007, Volume: 6, Issue:4

Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Invasiveness; Quinazolines; Receptors, Bombesin; Signal Transduction; Tumor Stem Cell Assay

2007